https://www.selleckchem.com/pr....oducts/apo866-fk866.
The primary safety end point is freedom from major adverse cardiovascular events (composite of cardiac death, myocardial infarction, and target vessel revascularization) at 30 days compared to a prespecified performance goal. The primary effectiveness end point is procedural success without in-hospital major adverse cardiovascular events. Enrollment will complete early in 2020 with clinical follow-up ongoing for 2 years. CONCLUSION Disrupt CAD III will evaluate the safety and effectiveness of the Shockwave coronary IVL catheter to
Gefällt mir
Kommentar
Teilen
